In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval

Clinical Endocrinology

Volumn 77, Issue 5, 2012, Pages 780-786

  Ulisse, Salvatore ^a   Baldini, Enke ^a   Sorrenti, Salvatore ^a   Barollo, Susi ^b   Prinzi, Natalie ^a   Catania, Antonio ^a   Nesca, Angela ^a   Gnessi, Lucio ^a   Pelizzo, Maria R ^c   Mian, Caterina ^c   De Vito, Corrado ^d   Calvanese, Anna ^a   Palermo, Silvio ^a   Persechino, Severino ^a   De Antoni, Enrico ^a   D'Armiento, Massimino ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MESSENGER RNA; RADIOACTIVE IODINE; UROKINASE; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER TISSUE; CHILD; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SEQUENCE ANALYSIS; THYROID CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA; CARCINOMA, PAPILLARY; CELL LINE; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; RATS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; THYROID NEOPLASMS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84867259293     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04465.x     Document Type: Article

References (30)

1. Ulisse, S., Baldini, E., Sorrenti, S., D'Armiento, M., (2009) The urokinase plasminogen activator system: a target for anti-cancer therapy. Current Cancer Drug Targets, 9, 32-71.
2. Duffy, M.J., (2004) The urokinase plasminogen activator system: role in malignancy. Current Pharmaceutical Design, 10, 39-49. (Pubitemid 38072742)
3. Shapiro, R.L., Duquette, J.G., Roses, D.F., et al,. (1996) Induction of primary cutaneous melanocytic neoplasms in the urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but not progress to malignant melanoma in uPA-deficient animals. Cancer Research, 56, 3597-3604. (Pubitemid 26251658)
4. Gutierrez, L.S., Schulman, A., Brito-Robinson, T., et al,. (2000) Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Research, 60, 5839-5847.
5. Foekens, J.A., Peters, H.A., Look, M.P., et al,. (2000) The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Research, 60, 636-643. (Pubitemid 30094561)
6. Look, M.P., van Putten, W.L., Duffy, M.J., et al,. (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. Journal of the National Cancer Institute, 94, 116-128. (Pubitemid 34121291)
7. Jänicke, F., Prechtl, A., Thomssen, C., et al,. (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Journal of the National Cancer Institute, 93, 913-920. (Pubitemid 32624648)
8. Harris, L., Fritsche, H., Mennel, R., et al,. (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25, 5287-2312.
9. Ulisse, S., Baldini, E., Sorrenti, S., et al,. (2011) High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 96, 504-508.
10. Ulisse, S., Baldini, E., Toller, M., et al,. (2006) Differential expression of the components of the plasminogen activating system in Human thyroid tumor derived cell lines and papillary carcinomas. European Journal of Cancer, 42, 2631-2638. (Pubitemid 44468383)
11. Horvatić Herceg, G., Herceg, D., Kralik, M., et al,. (2006) Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wiener Klinische Wochenschrift, 118, 601-609. (Pubitemid 46118428)
12. Buergy, D., Weber, T., Maurer, G.D., et al,. (2009) Urokinase receptor, MMP-1 and MMP-9 are marker to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. International Journal of Cancer, 125, 894-901.
13. Sherman, S.I., (2003) Thyroid carcinoma. Lancet, 361, 501-511. (Pubitemid 36173719)
14. Kinder, B.K., (2003) Well differentiated thyroid cancer. Current Opinion in Oncology, 15, 71-77. (Pubitemid 36135651)
15. Jemal, A., Siegel, R., Ward, E., et al,. (2009) Cancer statistics, 2009. Ca-A Cancer Journal for Clinicians, 59, 225-249.
16. Nikiforov, Y.E., Biddinger, P.W., &, Thompson, L.D.R., (2009) Diagnostic Pathology and Molecular Genetics of the Thyroid. Lippincott Williams & Wilkins, Philadelphia.
17. Trimboli, P., Ulisse, S., Graziano, F.M., et al,. (2006) Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid, 16, 1151-1155. (Pubitemid 44864490)
18. Passler, C., Scheuba, C., Prager, G., et al,. (2004) Prognostic factors of papillary and follicular thyroid cancers: differences in an iodine-replete endemic goiter region. Endocrine-Related Cancer 11, 131-139. (Pubitemid 38419728)
19. Gospodarowicz, M.K., Henson, D.E., Hutter, R.V.P., et al,. (2001) Prognostic Factors in Cancer, 2nd edn. Wiley-Liss, New York.
20. Eustatia-Rutten, C.F., Corssmit, E.P., Biermasz, N.R., et al,. (2006) Survival and death causes in differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 91, 313-319. (Pubitemid 43069155)
21. Xing, M., (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocrine Review, 28, 742-762. (Pubitemid 350294294)
22. Handkiewicz-Junak, D., Czarniecka, A., &, JarzÄb, B., (2010) Molecular prognostic markers in papillary thyroid cancer: current status and future directions. Molecular and Cellular Endocrinology 322, 8-28.
23. Shibru, D., Chung, K.W., &, Kebebew, E., (2008) Recent developments in the clinical application of thyroid cancer biomarkers. Current Opinion in Oncology, 20, 13-18. (Pubitemid 350190976)
24. Hedinger, C., Williams, E.D., &, Sobin, L.H., (1989) The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer, 63, 908-911. (Pubitemid 19063200)
25. Barollo, S., Pennelli, G., Vianello, F., et al,. (2010) BRAF in primary and recurrent papillary thyroid cancer: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. European Journal of Endocrinology, 163, 659-663.
26. Mitsutake, N., Knauf, J.A., Mitsutake, S., et al,. (2005) Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Research, 65, 2465-2473. (Pubitemid 40490159)
27. Chomczynsky, P., &, Sacchi, P., (1987) Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry, 162, 156-159.
28. Vandesompele, J., De Preter, K., Pattyn, F., et al,. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology, 18, RESEARCH0034.
29. Guerra, A., Sapio, M.R., Marotta, V., et al,. (2012) The primary occurrence of BRAFV600E Is a rare clonal event in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 97, 517-524.
30. Ito, Y., Yoshida, H., Maruo, R., et al,. (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocrine Journal, 56, 89-97.